• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Weekly, September 26, 2016

The CenterWatch Weekly, September 26, 2016

September 26, 2016
CenterWatch Staff

Mixed reactions to updated federal rules meant to increase clinical trials transparency

On September 16, the U.S. Department of Health and Human Services (HHS) issued a final rule dictating require­ments for registering certain clinical trials and posting summary results on ClinicalTrials.gov. The NIH also issued a complementary policy for regis­tering and reporting summary results to Clinical­Trials.gov for all NIH-funded trials. Although the new rule from the HHS does not govern phase I drug trials or small feasibility studies of devices, it applies to most interventional studies of drug, biological and device products that are regulated by the FDA. Essential elements in the final rule include providing additional types of adverse events, as well as the obligation to provide partici­pants’ race and ethnicity, if collected, along with the full protocol. The final rule concerns how and when the information is collected in a clinical trial, without placing any limits on how trials are designed and carried out, or even what data must be collected.

Eisai launches Andover innovative Medicines Institute for drug discovery acceleration

With an eye on the increasingly key role human genetics can play in drug development, Eisai has cre­ated the Eisai Andover innovative Medicines (AiM) Institute, which will focus on using genet­ics to develop targeted medicines for dementia, oncology and autoimmune diseases. The 90-scientist research and drug develop­ment unit is located in Andover, Massachusetts.

 

To read the full articles for this issue of The CenterWatch Weekly, please click here for subscription information.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing